Using separation-of-function mutations of TPP1 that inhibit telomerase binding while maintaining telomere capping, a region on the surface of TPP1, the TEL patch, is identified and found to be required for both binding telomerase and enhancing its processivity. The human chromosomal telomere-binding protein TPP1 protein binds telomeric single-stranded DNA and has an essential role in protecting chromosome ends. It is believed to both recruit and stimulate telomerase, the enzyme that replicates chromosome ends. Thomas Cech and colleagues show, using separation-of-function mutants of TPP1, that telomerase binding and telomere capping are independent functions. These mutants identify a small patch of amino acids on the surface of TPP1—the TEL patch—that is required both for binding telomerase and promoting its action. Telomerase is overexpressed in many cancers, making it a prime target for drug development. As it has been proven difficult to inhibit telomerase itself, the TEL patch provides a promising new strategy for anticancer therapy. Human chromosome ends are capped by shelterin, a protein complex that protects the natural ends from being recognized as sites of DNA damage and also regulates the telomere-replicating enzyme, telomerase1,2,3. Shelterin includes the heterodimeric POT1–TPP1 protein, which binds the telomeric single-stranded DNA tail4,5,6,7,8,9. TPP1 has been implicated both in recruiting telomerase to telomeres and in stimulating telomerase processivity (the addition of multiple DNA repeats after a single primer-binding event)9,10,11,12,13,14. Determining the mechanisms of these activities has been difficult, especially because genetic perturbations also tend to affect the essential chromosome end-protection function of TPP1 (refs 15, 16, 17). Here we identify separation-of-function mutants of human TPP1 that retain full telomere-capping function in vitro and in vivo, yet are defective in binding human telomerase. The seven separation-of-function mutations map to a patch of amino acids on the surface of TPP1, the TEL patch, that both recruits telomerase to telomeres and promotes high-processivity DNA synthesis, indicating that these two activities are manifestations of the same molecular interaction. Given that the interaction between telomerase and TPP1 is required for telomerase function in vivo, the TEL patch of TPP1 provides a new target for anticancer drug development.